BioMarin's Roctavian, once forecast to sell $50M to $150M last year, only pulls in a fraction of that
In April, BioMarin forecast that its new gene therapy Roctavian would bring in $50 million to $100 million in sales by the end of 2023 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
